Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Navidea Biopharmaceuticals Inc announces appointment of interim chief executive officer - Form 8-K


Monday, 19 May 2014 05:31pm EDT 

Navidea Biopharmaceuticals Inc:Says on May 15, it announced that it had asked Michael M. Goldberg, M.D., to serve as its interim chief executive officer.Says Goldberg has accepted the company’s offer to serve as interim chief executive officer.In connection with the restructuring of resources, the current chief executive officer, Mark J. Pykett, V.M.D., Ph.D., will take on a consulting role.Expects that Pykett will step down from his current position as chief executive officer on or before May 31 and that, following formal approval, Goldberg’s term as interim chief executive officer will officially commence on the same date. 

Company Quote

1.46
0.04 +2.82%
4:03pm EDT